Compare VanEck Australian Floating Rate ETF (FLOT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs TG Therapeutics Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.97, while TG Therapeutics Inc trades at $54.88 (market cap $8.64B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| FLOT | TGTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $51.09 | $59.06 |
52-Week Low | $50.72 | $26.39 |
Market Cap | — | $8.64B |
Enterprise Value | — | $8.88B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
